Tumor News and Research

RSS

Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link

A major systematic review and meta-analysis links higher BMI to increased risk of 19 cancer types, including leukemia, non-Hodgkin lymphoma, bladder cancer, and glioma, which were not previously recognized in major consensus reports. The study also reveals regional and sex-based variation in cancer risk, with genetic evidence generally supporting many observational links while highlighting the need for more diverse global cohorts.

17 Jun 2026

New biomarker predicts gastric cancer outcomes from CT scans

Researchers at the State University of Campinas (UNICAMP) in São Paulo, Brazil, have identified a new biomarker that may help determine the prognosis for patients with gastric cancer, the fifth most common type of cancer worldwide.

16 Jun 2026

New study uncovers how prostate cancer cells evade treatment

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, fueling drug resistance and disease progression.

16 Jun 2026

Purdue develops next-generation platform to accelerate cancer drug discovery

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.

16 Jun 2026

Engineered silica nanoparticles destroy prostate tumors in preclinical study

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing anti-tumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell College of Engineering.

15 Jun 2026

Blocking a specific protein improves CAR T-cell therapy success in patients with blood cancers

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

15 Jun 2026

Dual-target CAR T therapy triggers broad immune response in brain cancer

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival.

15 Jun 2026

Mutation in OTULIN gene causes rare childhood skin disease

An international team of researchers has identified a genetic cause for a rare inflammatory skin condition.

15 Jun 2026

Researchers identify vulnerabilities shared by surviving cancer cells

Cancer drugs can shrink fast-growing tumors. But sometimes a few tumor cells survive. These "persister" cells seed new tumors, forcing cancer patients into arduous cycles of testing and treatment.

12 Jun 2026

FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

12 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

Gut microbiome may determine bone loss severity in primary hyperparathyroidism

Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH).

12 Jun 2026

New genetic driver found for rare small intestinal cancers

A signaling system known as the Wnt pathway plays a central role in how cells in the intestine grow, divide, and renew themselves.

12 Jun 2026

Review outlines virtual tumor concept and next-generation immunotherapy

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

12 Jun 2026

New gel coating delivers anti-inflammatory antibodies directly to the esophagus

There are few treatment options available for people with disorders of the esophagus. Delivering drugs directly to this part of the body is difficult, so patients are usually treated with systemic drugs, which can have unwanted side effects.

12 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026

Circadian clock protein BMAL1 enhances inflammatory responses in immune cells

Daily life is shaped by the solar day, influencing when we wake up, eat, work, and sleep. Inside the body, a similar internal timing system -present in nearly every cell- known as the circadian clock, synchronizes many biological functions such as sleep, metabolism, hormone release, and even the immune system's activity.

11 Jun 2026

Viral DNA blood test accurately gauges post-surgery cancer recovery success

A new study by investigators from Mass General Brigham Cancer Institute found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after surgery and may benefit the most from additional treatments. Their results are published in Science Translational Medicine.

11 Jun 2026

Scientists reveal how cGAS-STING fuels brain inflammation and neurodegeneration

The cGAS-STING pathway is emerging as a key driver of chronic neuroinflammation through its effects on glial activation, neuronal stress, blood-brain barrier integrity, and type I interferon signaling. The review highlights why selective, context-dependent modulation of cGAS-STING could help treat neurodegenerative diseases, while preserving its essential roles in antiviral defense and tumor surveillance.

10 Jun 2026

Low-methionine diet shows promise against aggressive brain tumors

An unexpected lab observation led a team of scientists to discover how diet can influence survival in animal models of glioma, one of the most aggressive and deadly forms of brain cancer.

10 Jun 2026